Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
1342 | 2612 | 41.1 | 85% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1258 | 8423 | PHAGE DISPLAY//CATALYTIC ANTIBODIES//CATALYTIC ANTIBODY |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | SCFV | Author keyword | 95 | 34% | 9% | 228 |
2 | SINGLE CHAIN FV | Author keyword | 77 | 47% | 5% | 120 |
3 | PHAGE DISPLAY | Author keyword | 72 | 16% | 16% | 409 |
4 | ANTIBODY ENGINEERING | Author keyword | 72 | 37% | 6% | 157 |
5 | ANTIBODY LIBRARY | Author keyword | 46 | 58% | 2% | 53 |
6 | INTRABODIES | Author keyword | 34 | 61% | 1% | 36 |
7 | PHAGE ANTIBODY | Author keyword | 25 | 77% | 1% | 17 |
8 | IG THER Y CO | Address | 23 | 100% | 0% | 10 |
9 | TRIABODY | Author keyword | 23 | 100% | 0% | 10 |
10 | SCFV FRAGMENT | Author keyword | 22 | 67% | 1% | 20 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | SCFV | 95 | 34% | 9% | 228 | Search SCFV | Search SCFV |
2 | SINGLE CHAIN FV | 77 | 47% | 5% | 120 | Search SINGLE+CHAIN+FV | Search SINGLE+CHAIN+FV |
3 | PHAGE DISPLAY | 72 | 16% | 16% | 409 | Search PHAGE+DISPLAY | Search PHAGE+DISPLAY |
4 | ANTIBODY ENGINEERING | 72 | 37% | 6% | 157 | Search ANTIBODY+ENGINEERING | Search ANTIBODY+ENGINEERING |
5 | ANTIBODY LIBRARY | 46 | 58% | 2% | 53 | Search ANTIBODY+LIBRARY | Search ANTIBODY+LIBRARY |
6 | INTRABODIES | 34 | 61% | 1% | 36 | Search INTRABODIES | Search INTRABODIES |
7 | PHAGE ANTIBODY | 25 | 77% | 1% | 17 | Search PHAGE+ANTIBODY | Search PHAGE+ANTIBODY |
8 | TRIABODY | 23 | 100% | 0% | 10 | Search TRIABODY | Search TRIABODY |
9 | SCFV FRAGMENT | 22 | 67% | 1% | 20 | Search SCFV+FRAGMENT | Search SCFV+FRAGMENT |
10 | ANTIBODY LIBRARIES | 19 | 71% | 1% | 15 | Search ANTIBODY+LIBRARIES | Search ANTIBODY+LIBRARIES |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | BY PASSING IMMUNIZATION | 152 | 72% | 5% | 120 |
2 | SINGLE CHAIN FV | 106 | 34% | 10% | 258 |
3 | IMMUNOGLOBULIN VARIABLE DOMAINS | 80 | 64% | 3% | 79 |
4 | VARIABLE DOMAINS | 77 | 37% | 6% | 166 |
5 | SYNTHETIC REPERTOIRES | 71 | 76% | 2% | 50 |
6 | FV FRAGMENTS | 68 | 58% | 3% | 78 |
7 | FILAMENTOUS PHAGE | 63 | 27% | 8% | 206 |
8 | AFFINITY HUMAN ANTIBODIES | 57 | 62% | 2% | 59 |
9 | RESHAPING HUMAN ANTIBODIES | 43 | 56% | 2% | 53 |
10 | HIGH AFFINITY ANTIBODIES | 42 | 67% | 1% | 38 |
Journals |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | IMMUNOTECHNOLOGY | 15 | 35% | 1% | 34 |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Potent antibody therapeutics by design | 2006 | 525 | 134 | 34% |
Selecting and screening recombinant antibody libraries | 2005 | 447 | 158 | 60% |
scFv Antibody: Principles and Clinical Application | 2012 | 31 | 150 | 63% |
Identification of optimal protein binders through the use of large genetically encoded display libraries | 2015 | 1 | 65 | 55% |
MAKING ANTIBODIES BY PHAGE DISPLAY TECHNOLOGY | 1994 | 988 | 97 | 49% |
Stability engineering of antibody single-chain Fv fragments | 2001 | 274 | 121 | 60% |
Engineered antibody fragments and the rise of single domains | 2005 | 708 | 120 | 25% |
Therapeutic antibodies: successes, limitations and hopes for the future | 2009 | 151 | 79 | 30% |
Antibodies from phage antibody libraries | 2004 | 147 | 136 | 67% |
Antibody phage display technology and its applications | 1998 | 291 | 135 | 59% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | IG THER Y CO | 23 | 100% | 0.4% | 10 |
2 | ABT BIOTECHNOL | 7 | 39% | 0.5% | 13 |
3 | RECOMBINANT ANTIBODIES | 5 | 63% | 0.2% | 5 |
4 | GRP BIOTECHNOL ANTICORPS | 4 | 56% | 0.2% | 5 |
5 | ANESTHESIA PHARMACEUT CHEM | 3 | 26% | 0.4% | 11 |
6 | CRC DIAGNOST TECHNOL | 2 | 33% | 0.2% | 6 |
7 | BIOTECHNOL ANTICORPS | 2 | 38% | 0.2% | 5 |
8 | SINODANISH | 2 | 67% | 0.1% | 2 |
9 | ULTRASTRUCT IMMUNOL PARASITOL | 2 | 67% | 0.1% | 2 |
10 | RADIOIMMUNOTHER Y | 2 | 18% | 0.3% | 9 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000208462 | SINGLE DOMAIN ANTIBODY//NANOBODY//VHH |
2 | 0.0000196951 | CANONICAL STRUCTURES//CDR CONFORMATION//ANTIBODY STRUCTURE |
3 | 0.0000144952 | BISPECIFIC ANTIBODIES//CATUMAXOMAB//TRIFUNCTIONAL ANTIBODY |
4 | 0.0000142932 | SORBIN//NONCOMPETITIVE IMMUNOASSAY//PHAGE ANTI IMMUNOCOMPLEX ASSAY |
5 | 0.0000121105 | PHAGE DISPLAY//LANDSCAPE PHAGE//IN VIVO PHAGE DISPLAY |
6 | 0.0000091102 | PROTEIN ATLAS//PREST//HUMAN PROTEIN ATLAS |
7 | 0.0000083178 | IMMUNOCYTOKINES//IMMUNOCYTOKINE//PHILOCHEM AG |
8 | 0.0000082008 | AFFIBODY MOLECULE//AFFIBODY MOLECULES//AFFIBODY |
9 | 0.0000079280 | CELL SURFACE DISPLAY//SURFACE DISPLAY//CELL SURFACE ENGINEERING |
10 | 0.0000072943 | IMGT//UPR CNRS 1142//CNRSUPR 1142 |